Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results

Abstract The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan® Low Density Arra...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2012-09, Vol.36 (9), p.1134-1140
Main Authors: Franiak-Pietryga, Ida, Maciejewski, Henryk, Wolowiec, Dariusz, Salagacka, Aleksandra, Blonski, Jerzy Z, Janus, Agnieszka, Kotkowska, Aleksandra, Wawrzyniak, Ewa, Ghia, Paolo, Mirowski, Marek, Robak, Tadeusz, Korycka-Wolowiec, Anna
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antibodies, Monoclonal, Murine-Derived - adverse effects
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
Apoptosis - drug effects
Apoptosis - genetics
Chronic lymphocytic leukemia
Cladribine - administration & dosage
Cladribine - adverse effects
Cluster Analysis
Cyclophosphamide - administration & dosage
Cyclophosphamide - adverse effects
DNA Mutational Analysis
Female
Gene Expression Profiling
Gene Expression Regulation, Leukemic - drug effects
Genes, Immunoglobulin Heavy Chain - genetics
Hematology, Oncology and Palliative Medicine
Humans
IGHV mutation
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Male
Microarray
Middle Aged
Pilot Projects
Rituximab
V(D)J Recombination - drug effects
V(D)J Recombination - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The study was aimed to investigate modifications of apoptotic gene expression profile by microarray technique in 10 patients with chronic lymphocytic leukemia by treatment with rituximab, cladribine and cyclophosphamide (RCC) according to IGHV mutational status. The TaqMan® Low Density Array for 96 gene transcripts was used. Those modifications followed two distinctive patterns largely overlapping the IGHV mutational status. In the IGHV -mutated group, the expression of many proapoptotic genes increased after treatment as compared to initial value. Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2012.04.026